Have any questions? 706-721-6582 or cts@augusta.edu
- DISRUPT CF-301-105: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis
Clinical Trial
DISRUPT CF-301-105: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis
This study will look at how safe, effective, and tolerable a new IV drug called exebacase is, when given in addition to standard of care therapy, to patients with Staph. aureus blood stream infections, including infective endocarditis.
Eligibility Criteria
- INCLUSION: 1. Adults age 18 years or older with blood cultures showing confirmed or possible staph. aureus infection, and at least 2 signs or symptoms of staph. aureus infection. 2. Must have one or more of known risk factors/causes of staph. aureus infection. EXCLUSION: 1. No use of specified medications within protocol-defined time periods. 2. No current and/or past history of health conditions not allowed by the study.
RESEARCH. INNOVATION. DISCOVERY.